Catalent to Acquire RheinCell Therapeutics

Article

Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.

Catalent announced on June 24, 2021 an agreement to acquire RheinCell Therapeutics GmbH, a Langenfeld, Germany-based developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs), further expanding its custom cell therapy process development and manufacturing capabilities.

In making the announcement, Catalent reported that the acquisition will allow it to offer the building blocks to scale iPSC-based cell therapies and reduce barriers to entry to the clinic for therapeutic companies.

iPSC cell types can address a number of therapeutic indications. RheinCell has researched and developed full GMP human leukocyte antigen-matched cell banks.

Upon closing, which is expected before the end of 2021, RheinCell’s current employees will join Catalent’s Cell & Gene Therapy business.

Source: Catalent

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.